Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

WONDFO

Wondfo is a high-tech biological company focusing providing professional products and services for rapid diagnosis an... read more Featured Products: More products

Download Mobile App





Wondfo Exhibits Automatic Bench-Top CLIA Analyzers for POC Testing at AACC 2022

By LabMedica International staff writers
Posted on 26 Jul 2022

Wondfo (Guangzhou, China) will be exhibiting its automatic bench-top chemiluminescence immunoassay (CLIA) analyzers with advanced features for point of care (POC) testing at the 2022 AACC Clinical Lab Expo. More...



At AAC 2022, Wondfo is presenting its compact and automatic Accre 8 and Accre 90 CLIA bench-top analyzers which are 70% smaller than ordinary CLIA analyzers. With a single-dose reagent cartridge, the analyzers allow 600 days MTBF, requiring no extra consumables. The Accre 8 and Accre 90 enjoy both simple operation requiring only 30-minute training and reliable calibration & quality control system. Both the analyzers have a TAT time of 12-40 minutes and offer high sensitivity.

The Accre 8 has a throughput of up to 36 tests/hour and offers carry-over prevention. The Accre 90 has a throughput of up to 96 tests/hour and enables simultaneous processing of difference parameters with carry-over prevention. The Accre 8 and Accre 90 are designed for multiple application scenarios in emergency care, primary care and laboratories. Both the analyzers offer a broad menu of tests in the areas of thyroid, fertility, tumors, infectious diseases, cardiac, anemia, inflammation, bone metabolism and glycol metabolism.
 

Related Links:
Wondfo 


New
Gold Member
Collection and Transport System
PurSafe Plus®
Portable Electronic Pipette
Mini 96
Gold Member
Cardiovascular Risk Test
Metabolic Syndrome Array I & II
Gold Member
Hematology Analyzer
Medonic M32B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: LungCanSeek demonstrated an overall sensitivity of 83.5% and specificity of 90.3% in detecting lung cancer (Photo courtesy of AdobeStock)

New Blood Test Offers Affordable and Accurate Early Detection of Lung Cancer

Lung cancer remains the leading cause of cancer-related deaths worldwide, largely because most cases are diagnosed at advanced stages when treatment options are limited. Early detection significantly improves... Read more

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The TriVerity IVD test includes the TriVerity cartridge and the Myrna instrument (Photo courtesy of Inflammatix)

Blood-Based Immune Cell Signatures Could Guide Treatment Decisions for Critically Ill Patients

When a patient enters the emergency department in critical condition, clinicians must rapidly decide whether the patient has an infection, whether it is bacterial or viral, and whether immediate treatment... Read more

Industry

view channel
Image: The collaboration supports clinical validation and regulatory submissions of the new T1D 4-plex assay on Revvity’s GSP instrument (Photo courtesy of Revvity)

Revvity and Sanofi Collaborate on Program to Revolutionize Early Detection of Type 1 Diabetes

Type 1 diabetes (T1D) is a lifelong autoimmune condition in which the immune system destroys the pancreas’s insulin-producing beta cells, leading to dependence on insulin therapy. Early detection is critical... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.